BU-NOT-SET

CONTACT US
Inhibition of 19S proteasome deubiquitinating activity in Schistosoma mansoni affects viability, oviposition, and structural changes
  • Drug substance
Eyes
Insight
The demand for antibiotics and its impact on the pharmaceutical industry since the outbreak of COVID-19
  • Industry trends
Eyes
Insight
Women in leadership
  • Corporate
Eyes
Insight
The state of the oral solid dose development and manufacturing market
  • Drug product
Eyes
Insight
Characterising APIs is Essential for Combo Drug Formulations
  • Drug substance
Eyes
Insight
Outsourcing stability testing
  • Analytical chemistry
Eyes
Insight
Brexit: What’s next for UK pharma?
  • Industry trends
Eyes
Insight
Navigating approval filings choppy international waters
  • Drug substance
Eyes
Insight
Regulatory requirements for drug substances
  • Drug substance
Product check
Insight
Insight
  • Manufacturing
Countdown to EU FMD deadline
Fact sheet
  • Manufacturing
Stand-alone serialisation services
Insight
  • Industry trends
Post-Brexit medicines - stuck in the UK?
Insight
  • Industry trends
Brexit: What will it mean for the regulation of medicines?
Insight
  • Analytical chemistry
Stability study trends - Outsourcing stability studies
Insight
  • Industry trends
The EMA relocation: Brexit and the UK's pharmaceutical industry
Insight
  • Drug product
Prevention not cure: avoiding a European prescription opioid epidemic
Insight
  • Manufacturing
Six months and counting: industry views
Insight
  • Manufacturing
Six months until DSCSA… industry comments